| Name | Title | Contact Details |
|---|
Established in 1946 as well as being family owned and operated since 1946, the Fletcher Jones Company has grown into one of the largest and most respected automotive groups in the world. Our Preferred Owner Benefits include many amenities such as a complimentary Mercedes-Benz courtesy vehicle and a complimentary hand car wash.
When it comes to the world of automotive components, JVIS has continued to be the supplier of choice for leading global brands. Why? Were fast. Were flexible. Were everywhere. With our extensive art-to-part capabilities, we can do whatever it takes to help our customers get the solution they need. And facilities around the world and an international network of dedicated partners — we can provide global services with localized support you cant get from other suppliers. Thats great news for both your production line and bottom line. Whether you need a sleek new exterior part or a complete interior solution that creates a more comfortable ride, our team of experts can quickly design, produce and deliver exactly what you need.
FMI is a full-service contract manufacturing company established in 1992, specializing in the formulation, manufacturing, and packaging of prestige products in the personal care, home care, and fragrance markets. They provide a comprehensive range of services, including product development, formulation, manufacturing, filling, warehousing, shipping, and third-party logistics. This allows clients to efficiently bring their products to market with personalized attention. FMIs expertise covers a wide array of products, such as skin care items, fragrances, cleaning products, sun care solutions, air fresheners, mens grooming products, laundry detergents, dietary supplements, hair care, lip balm packaging, and bath and shower essentials. They position themselves as a key partner for beauty and personal care companies, offering the capabilities of a large manufacturer combined with the personal touch of a smaller company. Their clients benefit from a hassle-free process from initial product conception to final delivery.
Creative Bus Sales is now Model 1 Commercial Vehicles. Nothing about passion or our leadership has changed, and our brand represents the creativity, expertise, and vision we put to work for customers across the U.S. As the largest bus and commercial transit dealership in the U.S., Model 1 is at the forefront of solving commercial and community transportation issues with visionary thinking – including not just vehicles but also distribution, parts, service, F&I, and more. Strong partnerships with more than 20 top manufacturers, the largest in-stock vehicle inventory in the country, and a nationwide team of experts, means theres no problem too big or too unique to solve together. Model 1 is the blueprint for creative commercial vehicle solutions. See why at model1.com.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.